131 related articles for article (PubMed ID: 26752869)
21. Drug-Induced Liver Injury from Anti-Tuberculosis Treatment: A Retrospective Cohort Study.
Zhao H; Wang Y; Zhang T; Wang Q; Xie W
Med Sci Monit; 2020 Mar; 26():e920350. PubMed ID: 32145061
[TBL] [Abstract][Full Text] [Related]
22.
Petros Z; Kishikawa J; Makonnen E; Yimer G; Habtewold A; Aklillu E
Front Pharmacol; 2017; 8():90. PubMed ID: 28289388
[TBL] [Abstract][Full Text] [Related]
23. Spectrum of Cutaneous Adverse Drug Reactions to Anti-tubercular Drugs and Safe Therapy after Re-challenge - A Retrospective Study.
Sharma RK; Verma GK; Tegta GR; Sood S; Rattan R; Gupta M
Indian Dermatol Online J; 2020; 11(2):177-181. PubMed ID: 32477975
[TBL] [Abstract][Full Text] [Related]
24. Occult hepatitis B virus infection: clinical implications in tuberculosis treatment.
Trigo C; do Brasil PE; Costa MJ; de Castro L
J Viral Hepat; 2016 Dec; 23(12):1027-1035. PubMed ID: 27624908
[TBL] [Abstract][Full Text] [Related]
25. Spectrum of anti tubercular therapy induced cutaneous adverse drug reactions and its management through rechallenge: A prospective study at a Tertiary Care Centre.
Modi B; Modha J
Indian J Tuberc; 2022 Oct; 69(4):470-475. PubMed ID: 36460378
[TBL] [Abstract][Full Text] [Related]
26. The role of chronic viral hepatitis on tuberculosis treatment interruption.
Chua AP; Lim LK; Gan SH; Chee CB; Wang YT
Int J Tuberc Lung Dis; 2018 Dec; 22(12):1486-1494. PubMed ID: 30606322
[TBL] [Abstract][Full Text] [Related]
27. Predicting Antituberculosis Drug-Induced Liver Injury Using an Interpretable Machine Learning Method: Model Development and Validation Study.
Zhong T; Zhuang Z; Dong X; Wong KH; Wong WT; Wang J; He D; Liu S
JMIR Med Inform; 2021 Jul; 9(7):e29226. PubMed ID: 34283036
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis B or hepatitis C co-infection in individuals infected with human immunodeficiency virus and effect of anti-tuberculosis drugs on liver function.
Padmapriyadarsini C; Chandrabose J; Victor L; Hanna LE; Arunkumar N; Swaminathan S
J Postgrad Med; 2006; 52(2):92-6. PubMed ID: 16679670
[TBL] [Abstract][Full Text] [Related]
29. Viral hepatitis prevalence in patients with active and latent tuberculosis.
Nooredinvand HA; Connell DW; Asgheddi M; Abdullah M; O'Donoghue M; Campbell L; Wickremasinghe MI; Lalvani A; Kon OM; Khan SA
World J Gastroenterol; 2015 Aug; 21(29):8920-6. PubMed ID: 26269682
[TBL] [Abstract][Full Text] [Related]
30. Utility of Liver Biopsy in the Diagnosis and Management of Possible Drug-Induced Liver Injury in Patients Receiving Antituberculosis Therapy: A Retrospective Study.
Gualano G; Zace D; Mosti S; Mencarini P; Musso M; Libertone R; Cerva C; Goletti D; Rianda A; Del Nonno F; Falasca L; Palmieri F
Infect Dis Rep; 2023 Nov; 15(6):735-746. PubMed ID: 38131879
[TBL] [Abstract][Full Text] [Related]
31. Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection.
Tetrault JM; Tate JP; Edelman EJ; Gordon AJ; Lo Re V; Lim JK; Rimland D; Goulet J; Crystal S; Gaither JR; Gibert CL; Rodriguez-Barradas MC; Fiellin LE; Bryant K; Justice AC; Fiellin DA
J Subst Abuse Treat; 2016 Sep; 68():62-7. PubMed ID: 27431048
[TBL] [Abstract][Full Text] [Related]
32. Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury.
Devarbhavi H; Singh R; Patil M; Sheth K; Adarsh CK; Balaraju G
J Gastroenterol Hepatol; 2013 Jan; 28(1):161-7. PubMed ID: 23020522
[TBL] [Abstract][Full Text] [Related]
33. Appropriate chemopreventive strategy for anti-tubercular therapy related liver injury is unsettled: Results from a systematic review and network meta-analysis.
Singh AK; Verma S; Kumar-M P; Soni H; Sharma S; Sharma S; Patil A; Sharma V
Expert Rev Clin Pharmacol; 2020 Nov; 13(11):1253-1262. PubMed ID: 33043729
[TBL] [Abstract][Full Text] [Related]
34. Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis.
Park WB; Kim W; Lee KL; Yim JJ; Kim M; Jung YJ; Kim NJ; Kim DH; Kim YJ; Yoon JH; Oh MD; Lee HS
J Infect; 2010 Oct; 61(4):323-9. PubMed ID: 20670648
[TBL] [Abstract][Full Text] [Related]
35. Development of a prediction system for anti-tuberculosis drug-induced liver injury in Japanese patients.
Mushiroda T; Yanai H; Yoshiyama T; Sasaki Y; Okumura M; Ogata H; Tokunaga K
Hum Genome Var; 2016; 3():16014. PubMed ID: 27340556
[TBL] [Abstract][Full Text] [Related]
36. The effect of statins on the risk of anti-tuberculosis drug-induced liver injury among patients with active tuberculosis: A cohort study.
Huang CK; Huang JY; Chang CH; Tsai SJ; Shu CC; Wang HC; Chien KL
J Microbiol Immunol Infect; 2024 Jun; 57(3):498-508. PubMed ID: 38632021
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis C virus infection: a challenge in the complex management of two cases of multidrug-resistant tuberculosis.
Musso M; Mosti S; Gualano G; Mencarini P; Urso R; Ghirga P; Rianda A; Del Nonno F; Goletti D; Palmieri F
BMC Infect Dis; 2019 Oct; 19(1):882. PubMed ID: 31640579
[TBL] [Abstract][Full Text] [Related]
38. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
39. Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study.
Sinha S; Gupta K; Tripathy S; Dhooria S; Ranjan S; Pandey RM
BMC Infect Dis; 2017 Dec; 17(1):761. PubMed ID: 29228918
[TBL] [Abstract][Full Text] [Related]
40. Idiosyncratic drug-induced liver injury: an overview.
Hussaini SH; Farrington EA
Expert Opin Drug Saf; 2007 Nov; 6(6):673-84. PubMed ID: 17967156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
